Compare Alexandria Real Estate Equities Inc (ARE) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alexandria Real Estate Equities Inc vs Inovio Pharmaceuticals Inc — how do they compare? Alexandria Real Estate Equities Inc trades at $48.07 (market cap $8.28B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: Alexandria Real Estate Equities Inc is far larger — about 105.4× Inovio Pharmaceuticals Inc's market cap, and Alexandria Real Estate Equities Inc pays a 5.99% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ARE | INO | |
|---|---|---|
Market Cap | $8.28B | $78.55M |
Sector | Real Estate | Health |
52-Week High | $87.45 | $2.87 |
52-Week Low | $40.41 | $0.66 |
Enterprise Value | $20.98B | $49.56M |
Dividend Yield | 5.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alexandria Real Estate Equities (ARE) trades at $48.01, down 0.7% on the day, with a bearish technical signal and mixed fundamentals. The stock shows negative profitability with a net income margin of -37.12% and ROE of -6.29% for 2025, though it maintains a strong gross margin of 67.28%. Recent Q2 2026 earnings missed EPS expectations but beat on FFO, with leasing momentum improving. The current price is near the analyst low target of $48.00, with support at $47 and resistance at $49.
Outlook remains cautious due to persistent net losses and high debt, but a 36% analyst buy rating and recent institutional acquisitions suggest potential recovery if leasing trends and FFO guidance hold. Key risks include occupancy pressures, legal scrutiny, and macroeconomic sensitivity. The stock presents a speculative opportunity for value investors betting on a real estate turnaround.
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alexandria Real Estate Equities Inc
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.
Read more on ARE →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
